一种定量DOPA脱碳酶生物标志物用于诊断勒维体疾病
Katharina Bolsewig1,2, Giovanni Bellomo3,4, Yanaika S Hok-A-Hin5,6
1Neurochemistry Laboratory, Laboratory Medicine Department, Amsterdam Neuroscience, VU University Medical Centers, Amsterdam UMC, Amsterdam, the Netherlands. k.bolsewig@amsterdamumc.nl.
Nature medicine
|February 16, 2026
概括
大脑脊髓液DOPA脱碳酶 (DDC) 是诊断勒维体痴呆症 (DLB) 和帕金森病 (PD) 的有前途的生物标志物. 新的免疫测试显示,DLB和PD患者的CSF DDC水平升高,有助于差异诊断.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 临床诊断 临床诊断 临床诊断
背景情况:
- 精确诊断勒维体痴呆症 (DLB) 是一个挑战,影响治疗决策.
- DOPA脱碳酶 (DDC) 是DLB和帕金森病 (PD) 的潜在脑脊液 (CSF) 生物标志物.
- 对于临床实施CSF DDC生物标志物的定量测试是必要的.
研究的目的:
- 开发和临床验证用于DLB和PD诊断的DDC免疫试验.
- 评估CSF DDC水平的诊断准确性,以区分DLB和PD与对照和阿尔茨海默病 (AD) 的区别.
- 调查CSF DDC水平,运动障碍和α-synuclein病理之间的相关性.
主要方法:
- 开发了两个DDC免疫测试.
- 在三个队列中进行临床验证,共有740名参与者.
- 分析CSF DDC水平,多巴胺载体成像和尸检确认的病理.
主要成果:
- 与对照和AD相比,DLB和PD的CSF DDC水平显著增加 (高达2.5倍).
- 开发的测试实现了差异诊断曲线下面面积>0.9的值.
- 在尸检确认的DLB中,增加的CSF DDC与运动障碍和α-synuclein病理相关.
结论:
- 脊髓脊髓 DDC 显示出作为生物标志物具有显著的潜力,可用于支持DLB和PD的诊断.
- 开发的DDC免疫测试已被验证用于临床实施.
- DDC在神经退行性疾病病理学中的作用,特别是其与α-synuclein的同局,需要进一步调查.
相关概念视频
01:24Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
01:15Parkinson's Disease: Overview
2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K